| abstract |
Hybrid proteins that have plasminogen and antithrombotic activating properties, including a specific coagulation action. This makes them very advantageous for the treatment of circulatory disorders related to the formation of fibrin clots due to an underlying tissue damage in the blood vessels that leads to myocardial infarctions, strokes, etc. Proteins are also disclosed, and methods for obtain them, which help dissolve blood clots by plasminogen activation in a manner dependent on plasmin or thrombin. In addition, they inhibit the activity and generation of thrombin through the intrinsic pathway of blood coagulation. Claim 1: A construction of a chimeric protein comprising epidermal growth factor type domains 4, 5 and 6 (EGF 4,5,6) of thrombomodulin fused to a thrombolytic protein selected from the group consisting of a streptokinase, a tissue plasminogen activator, a staphylokinase, a urokinase and derivatives and analogs thereof. |